Posterior reversible encephalopathy syndrome with essential thrombocythemia
A case report

Yunqiao Zhang, PhD, Xiang Lu, MD, Yanping Li, MD, Jie Wu, PhD, Ting Liu, MD, Xian Xie, MD, Xiaolin He, PhD, Yong Zeng, PhD

Abstract
Rationale: Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disease of the posterior subcortical white matter that manifests as headache, seizures, visual impairment, disturbance of consciousness, and changes in mental state. While PRES is associated with specific imaging findings involving the posterior circulation area of the brain. In the present study, we report the first case of PRES associated with essential thrombocythemia (ET).

Patient concerns: A 49-year-old man suddenly experienced headache, followed by the gradual appearance of consciousness disorders and mental behavior abnormalities. Neurological tests showed that the patient had a Glasgow Coma Scale score of 12, normal muscle strength and tension of the limbs, and was negative for meningeal irritation.

Diagnosis: Magnetic resonance imaging of the brain showed extensive vasogenic edema in the deep white matter of the right cerebellum and the left occipital and temporal lobes and a diagnosis of PRES was considered. Routine blood test showed that his platelet count was markedly increased, and the JAK2 V617F mutation analysis with allele-specific real-time polymerase chain reaction was positive. The bone marrow biopsy indicated an increasing number of megakaryocytes. These findings indicated ET.

Interventions: PRES was treated with a dehydrating agent and supportive and symptomatic treatments. Aspirin tablets were prescribed to address the patient’s ET.

Outcome: After treatment, the abnormal findings on head imaging were completely reversed. His neurological symptoms were completely relieved.

Lessons: PRES may be correlated with ET; specifically, ET may trigger PRES and be a risk factor for the acute onset of neurological deficits.

Abbreviations: ET = essential thrombocythemia, PRES = posterior reversible encephalopathy syndrome.

Keywords: essential thrombocythemia, posterior reversible encephalopathy syndrome, neurological disease

1. Introduction
Posterior reversible encephalopathy syndrome (PRES) is an acute neurological disease first introduced by Hinchey et al in 1996.[1]

It is characterized by changes in mental state (stupor and confusion), headache, epilepsy, cortical blindness or other visual changes, and cerebellar ataxia.[2] Indicated by unique neuroimaging manifestations of white matter tractography abnormalities, PRES is usually induced by malignant hypertension or eclampsia, severe kidney disease, chemotherapy for malignant tumors, and immunosuppressive therapy following organ transplantation. Advances in magnetic resonance imaging (MRI) approaches have improved the detection of PRES. Consequently, the prognosis of the disease is usually satisfactory, and most patients can make a full recovery.[1]

Essential thrombocythemia (ET) is a chronic myeloproliferative disease characterized by the abnormal proliferation of megakaryocytes in the bone marrow and significant increases in platelet counts.[3–5] ET manifests as bleeding and thrombophilia and is associated with a high risk of thrombotic events.[3–5] Here we present a case of PRES with ET and discuss the possible association between the 2 diseases.

2. Case presentation
A 49-year-old Chinese man presented with a 5-day history of headache. On the 5th day, he was admitted to a local clinic where he underwent head computed tomography, which showed a low-density shadow in the left temporal lobe. His condition generally worsened over the following week. He began to experience
obvious unresponsiveness, irritability, and communication difficulties with family members and became increasingly unable to perform requested actions. Therefore, the patient was admitted to the inpatient department for further emergency treatment.

The patient had no history of hypertension; diabetes; coronary heart disease; or infectious diseases, such as hepatitis, tuberculosis, and typhoid. The physical examination revealed a relatively low blood pressure (130/80 mmHg) and a body temperature of 36.8° C. The patient was somnolent and unresponsive. His abilities to understand, calculate, recall, and orient himself had significantly diminished. Neurological tests showed that he had a Glasgow Coma Scale score of 12 and normal limb strength and muscle tension with no signs of meningeal irritation. Cerebrospinal fluid examination findings excluded a diagnosis of intracranial infection. Routine biochemical tests showed normal levels of electrolytes and blood sugar, and electroencephalography revealed no abnormalities. MRI showed long T1 and T2 signal in the right cerebellum as well as in the subcortical white matter of the left occipital and temporal lobes (Fig. 1). A fluid-attenuated inversion recovery (FLAIR) sequence showed high signal in the same brain area. Head magnetic resonance angiography showed no obvious abnormalities in the blood vessels. Routine blood tests revealed a platelet count of 896 × 10^9/L, white blood cell count of 15.97 × 10^9/L, red blood cell count of 4.48 × 10^12/L, and hemoglobin count of 134 g/L. C-reactive protein levels and erythrocyte sedimentation rates were normal. The thrombocytosis persisted during hospitalization. A bone marrow biopsy showed that the megakaryocytes in the bone marrow tissue were focally distributed and partially dispersed. While the morphology of megakaryocytes was diverse, most were abundant in the cytoplasm. Genetic analysis with allele-specific, real-time polymerase chain reaction was positive for the JAK2 V617F mutation and negative for the BCR-ABL1 or MPL W515L/K mutations and a diagnosis of ET was considered.

The patient was orally administered low doses of aspirin (100 mg/d) to treat the ET. Mannitol, furosemide, and supportive and symptomatic treatments were used to treat the brain edema. The patient recovered quickly after treatment. On the 9th day of hospitalization, the patient’s consciousness gradually returned to normal, and he was able to communicate normally. Neurological tests yielded a Glasgow Coma Scale score of 15. The second MRI examination revealed a significant reduction of leukoencephalopathy (Fig. 2). The patient’s condition had occurred suddenly and manifested clinically as headache and changes in his mental state. Head MRI revealed abnormal signals in the white matter of the occipital and temporal lobes and the cerebellum. Treatment significantly relieved the clinical symptoms of the patient. The second head MRI examination showed that the extent of the white matter edema was significantly reduced relative to that observed on the previous MRI. A diagnosis of PRES was considered. An additional MRI conducted in December 2015—the 34th day following admission—showed no abnormalities (Fig. 3). After discharge, the patient continued taking the prescribed aspirin at doses of 100 mg/d. Routine blood tests and assessments of coagulation function were conducted at 1-month intervals during the following 26 months of follow-up. No bleeding or vascular embolism was observed after discharge. Across follow-up, the patient had a platelet count of

Figure 1. The brain MRI images obtained on admission. The images confirmed extensive hyperintense lesions on the T2 sequence (vasogenic edema) with the involvement of the occipital and temporal lobes, as well as the cerebellum. MRI=magnetic resonance imaging.
Figure 2. The brain MRI images obtained on day 9 of hospitalization. MRI=magnetic resonance imaging.

Figure 3. The brain MRI images obtained on day 34 of hospitalization. MRI=magnetic resonance imaging.
increasing number of megakaryocytes. The patient during his hospitalization. The bone marrow biopsy indicated an abnormalities in red blood cell count or hemoglobin excluded reactive thrombocytopenia was excluded. The lack of anemia and patient chronic myeloid leukemia and acute lymphoblastic leukemia. The PRES can reportedly present without hypertension.[6] The patient, unlike previous reports of PRES, our patient was diagnosed to those previously reported. While we suspect a direct relationship between PRES and hypertension,[1] patients with right cerebellar lesions disappeared. These outcomes were similar middle-aged patients are more commonly incidence of ET.[11] Middle-aged patients are more commonly to those previously reported. While we suspect a direct relationship between PRES and hypertension, patients with remains poorly understood, endothelial dysfunction has been implicated in PRES.[11] Previous studies have found that the activation of endothelial cells is enhanced in ET and is more common in patients with JAK2 mutations.[12,17] Endothelial cells appear to respond to the pathological condition of patients with ET; since platelets have been shown to stimulate the endothelial-cell-mediated synthesis of PAI via transforming growth factor-

3. Discussion
To the best of our knowledge, this report is the first to document a case of PRES and ET. Hyperintense abnormalities in the left occipital and temporal lobes were observed on FLAIR. Hyperintensities in the right cerebellum were also observed on T2 and ADC. These neuroimaging findings indicated vasogenic edema. After treatment, the abnormal signal intensities in the left occipital and temporal lobes were significantly reduced, and the right cerebellar lesions disappeared. These outcomes were similar to those previously reported. While we suspect a direct relationship between PRES and hypertension,[11] patients with PRES can reportedly present without hypertension.[6–8] However, unlike previous reports of PRES, our patient was diagnosed with essential thrombocythemia (ET) during his hospitalization. The patient’s platelet count continued to exceed 450 × 10^9/L during his hospitalization. The bone marrow biopsy indicated an increasing number of megakaryocytes. The patient’s not having the BCR-ABL1 mutation could exclude a diagnosis of human chronic myeloid leukemia and acute lymphoblastic leukemia. The patient’s levels of C-reactive protein were normal. As the patient was determined to be positive for JAK2 V617F, a diagnosis of reactive thrombocytopenia was excluded. The lack of anemia and abnormalities in red blood cell count or hemoglobin excluded primary myofibrosis and polycythemia vera.

ET is a chronic myeloproliferative disorder characterized by a relatively benign clinical process.[9,10] However, the pathogenesis of ET remains unclear. Previous studies have reported that a point mutation on exon 14 of the JAK2 gene causes the formation of the JAK2 V617F transcript, which is closely related to the incidence of ET.[11] Middle-aged patients are more commonly afflicted with ET. Most of the patients have normal life expectancies, and a few patients develop acute leukemia.[9,10] Despite the lack of prospective data concerning ET, aspirin is recommended to reduce the enhanced vascular risk.[12,13]

The relationship between PRES and ET has not been previously reported or explored. While ET might increase the risk of stroke (acute ischemic stroke and hemorrhagic strokes),[5,14] whether and how ET influences PRES is unclear. Although the pathophysiological changes induced by PRES remain poorly understood, endothelial dysfunction has been implicated in PRES.[11] Previous studies have found that the activation of endothelial cells is enhanced in ET and is more common in patients with JAK2 mutations.[12,17] Endothelial cells appear to respond to the pathological condition of patients with ET; since platelets have been shown to stimulate the endothelial-cell-mediated synthesis of PAI via transforming growth factor-

The incidence of ET and PRES is low, no mature animal models of these 2 diseases exist at present.

Author contributions
Conceptualization: Yunqiao Zhang, Zixiang Lu, Yanping Li, Ting Liu.
Data curation: Ting Liu, Xiaolin He, Yong Zeng.
Investigation: Yunqiao Zhang, Zixiang Lu.
Methodology: Jie Wu, Ting Liu.
Resources: Yunqiao Zhang, Ting Liu.
Software: Yunqiao Zhang, Yong Zeng.
Supervision: Xian Xie, Xiaolin He, Yong Zeng.
Writing – original draft: Yunqiao Zhang, Zixiang Lu, Yanping Li.
Writing – review & editing: Xiaolin He, Yong Zeng.
Yunqiao Zhang orcid: 0000-0002-7402-4844

References
[1] Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoen cephalopathy syndrome. N Engl J Med 1996;334:494–500.
[2] Granata G, Greco A, Iannella G, et al. Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2015;14:830–6.
[3] Hobbs CM, Manning H, Bennett C, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013;122:3787–90.
[4] Posfai É, Marton I, Szőke A, et al. Stroke in essential thrombocytemia. J Neurol Sci 2014;336:260–2.
[5] Alvarez-Larrán A, Cervantes F, Bellas J, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myofibrosis in 126 patients. Leukemia 2007;21:1218–23.
[6] Satthyarayana SO, Sreenivas PK, Uddappa AM. Posterior reversible encephalopathy syndrome complicating diabetic ketoacidosis. Indian Pediatr 2019;56:244–6.
[7] Hirahama H, Iwamoto M, Ozawa T, et al. Posterior reversible encephalopathy syndrome with stroke in puerperal woman with high titer of anti-phospholipid IgM antibody. Case Rep Obstet Gynecol 2018;2018:7438676.
[8] Henderson RD, Rajah T, Nicol AJ, et al. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003;60:326–8.
[9] Landolfi R, Di Gennaro L, Novarese L. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocytemia and polycythemia vera: current insights and rationale for future studies. Semin Thromb Hemost 2006;32:251–9.
[10] Grieshammer M, Rangert M, Grünwald M. Current treatment practice for essential thrombocythaemia in adults. Expert Opin Pharmacother 2001;2:385–93.
[11] Greenfield G, McPherson S, Mills K, et al. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med 2018;16:360.
[12] Harrison CN, Rareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352–75.
[13] Barbu T, Barosi G, Birgeggaard G, et al. Philadelphia-negative classical myeloproliferative neoplasm: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761–70.
[14] Sugiyama M, Ueno Y, Kamo H, et al. Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocytemia: two case reports and a literature review. J Neurol Sci 2019;398:1869–78.
[15] Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015;14:914–25.
[16] Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocytemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169–75.
[17] Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009;84:102–8.

[18] Fujii S, Lucore CL, Hopkins WE, et al. Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications. Am J Cardiol 1989;63:1505–11.

[19] Fujii S, Hopkins WE, Sobel BE. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type I in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991;83:645–51.

[20] Slivka SR, Loskutoff DJ. Platelets stimulate endothelial cells to synthesize type I plasminogen activator inhibitor. Evaluation of the role of transforming growth factor p. Blood 1991;77:1013–9.

[21] Friedenberg R, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol 1992;40:283–9.

[22] Medinger M, Skoda R, Gratzwohl A, et al. Angiogenesis and vascular endothelial growth factor-receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009;146:150–7.

[23] Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012;2012:571–81.

[24] Grechowa I, Horke S, Wallrath A, et al. Human neutrophil elastase induces endothelial cell apoptosis by activating the PERK-CHOP branch of the unfolded protein response. FASEB J 2017;31:3868–81.

[25] Tong D, Yu M, Guo L, et al. Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients. Ann Hematol 2018;97:605–16.